Literature DB >> 29572563

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.

Madelé van Dyk1, Jean-Claude Marshall2, Michael J Sorich1, Linda S Wood2, Andrew Rowland3.   

Abstract

PURPOSE: Cytochrome P450 (CYP) 3A4 is responsible for the metabolism of more than 30% of clinically used drugs. Inherent between subject variability in clearance of CYP3A4 substrates is substantial; by way of example, midazolam clearance varies by > 10-fold between individuals before considering the impact of extrinsic factors. Relatively little is known about inter-racial variability in the activity of this enzyme.
METHODS: This study assessed inter-racial variability in midazolam exposure in a cohort (n = 30) of CYP3A genotyped, age-matched healthy males of Caucasian and South Asian ancestries. Midazolam exposure was assessed at baseline, following 7 days of rifampicin and following 3 days of clarithromycin.
RESULTS: The geometric mean baseline midazolam area under the plasma concentration curve (AUC0-6) in Caucasians (1057 μg/L/min) was 27% greater than South Asians (768 μg/L/min). Similarly, the post-induction midazolam AUC0-6 in Caucasians (308 μg/L/min) was 50% greater than South Asians (154 μg/L/min), while the post-inhibition midazolam AUC0-6 in Caucasians (1834 μg/L/min) was 41% greater than South Asians (1079 μg/L/min). The difference in baseline AUC0-6 between Caucasians and South Asians was statistically significant (p ≤ 0.05), and a trend toward significance (p = 0.067) was observed for the post-induction AUC0-6 ratio, in both unadjusted and genotype adjusted analyses.
CONCLUSIONS: Significantly higher midazolam clearance was observed in healthy age-matched males of South Asian compared to Caucasian ancestry that was not explained by differences in the frequency of CYP3A genotypes.

Entities:  

Keywords:  Caucasian; Cytochrome P450 3A4; Inducibility; Inter-racial variability; Pharmacokinetics; South Asian

Mesh:

Substances:

Year:  2018        PMID: 29572563     DOI: 10.1007/s00228-018-2450-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

Review 1.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 2.  Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

Authors:  Andrew Rowland; Madelé van Dyk; Arduino A Mangoni; John O Miners; Ross A McKinnon; Michael D Wiese; Angela Rowland; Ganessan Kichenadasse; Howard Gurney; Michael J Sorich
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-09-01       Impact factor: 4.481

3.  Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Authors:  Angela Rowland; Madelé van Dyk; David Warncken; Arduino A Mangoni; Michael J Sorich; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

4.  CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.

Authors:  Rajaa A Mirghani; Jane Sayi; Eleni Aklillu; Annika Allqvist; Mary Jande; Agneta Wennerholm; Jaran Eriksen; Virginie M M Herben; Barry C Jones; Lars L Gustafsson; Leif Bertilsson
Journal:  Pharmacogenet Genomics       Date:  2006-09       Impact factor: 2.089

5.  Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment.

Authors:  Mariano Ferraresso; Stefano Turolo; Mirco Belingheri; Amedea Silvia Tirelli; Ivan Cortinovis; Silvano Milani; Alberto Edefonti; Luciana Ghio
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

Review 6.  Genetic variability in CYP3A5 and its possible consequences.

Authors:  Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry.

Authors:  V Perera; A S Gross; A J McLachlan
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

Review 9.  PM frequencies of major CYPs in Asians and Caucasians.

Authors:  Takaharu Mizutani
Journal:  Drug Metab Rev       Date:  2003 May-Aug       Impact factor: 4.518

Review 10.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

Authors:  Masoud Jamei; Gemma L Dickinson; Amin Rostami-Hodjegan
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

View more
  10 in total

1.  Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR.

Authors:  Hobart Owen Ng Tsai; Janice Jia Ni Goh; Jernice Wan Xin Aw; Yingying Lin; Alan Yean Yip Fong; Lee Len Tiong; Doreen Su-Yin Tan
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

2.  Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.

Authors:  Asha J Kapetas; Michael J Sorich; A David Rodrigues; Andrew Rowland
Journal:  AAPS J       Date:  2019-06-19       Impact factor: 4.009

3.  Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Authors:  Andrew Rowland; Warit Ruanglertboon; Madelé van Dyk; Dhilushi Wijayakumara; Linda S Wood; Robyn Meech; Peter I Mackenzie; A David Rodrigues; Jean-Claude Marshall; Michael J Sorich
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

Review 4.  Nuances to precision dosing strategies of targeted cancer medicines.

Authors:  Ashley M Hopkins; Bradley D Menz; Michael D Wiese; Ganessan Kichenadasse; Howard Gurney; Ross A McKinnon; Andrew Rowland; Michael J Sorich
Journal:  Pharmacol Res Perspect       Date:  2020-08

5.  Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate.

Authors:  Madelé van Dyk; Asha J Kapetas; Ashley M Hopkins; A David Rodrigues; Manoli Vourvahis; Michael J Sorich; Andrew Rowland
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

Review 6.  Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.

Authors:  C Louwrens Braal; Elisabeth M Jongbloed; Saskia M Wilting; Ron H J Mathijssen; Stijn L W Koolen; Agnes Jager
Journal:  Drugs       Date:  2020-12-28       Impact factor: 9.546

7.  How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti-Hepatitis B Virus Drug.

Authors:  Valérie Cosson; Sheng Feng; Felix Jaminion; Annabelle Lemenuel-Diot; Neil Parrott; Axel Paehler; Qingyan Bo; Yuyan Jin
Journal:  Clin Pharmacol Ther       Date:  2021-03-10       Impact factor: 6.875

8.  Inhibitory Effect of Lygodium Root on the Cytochrome P450 3A Enzyme in vitro and in vivo.

Authors:  Yunfang Zhou; Ailian Hua; Quan Zhou; Peiwu Geng; Feifei Chen; Lianhe Yan; Shuanghu Wang; Congcong Wen
Journal:  Drug Des Devel Ther       Date:  2020-05-19       Impact factor: 4.162

9.  Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo.

Authors:  Yiran Wang; Changxiong Wang; Shuanghu Wang; Quan Zhou; Dapeng Dai; Jihua Shi; Xue Xu; Qingfeng Luo
Journal:  Front Pharmacol       Date:  2020-02-14       Impact factor: 5.810

Review 10.  Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.

Authors:  Fitri Fareez Ramli
Journal:  Bosn J Basic Med Sci       Date:  2021-04-01       Impact factor: 3.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.